Argent BioPharma Limited (RGT.L)
GBp 6.0
(-7.69%)
GBp 6.0
(-7.69%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | -6.28 Million | -6.89 Million | -6.51 Million | -5.54 Million | -3.5 Million |
| Net Income | - | -10.92 Million | -11.53 Million | -8.62 Million | -10.45 Million | -6.07 Million |
| Depreciation & Amortization | - | 394.54 Thousand | 229.73 Thousand | 349.32 Thousand | 268.09 Thousand | 143.21 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | 1.08 Million | 1.11 Million | -1.9 Million | 293.58 Thousand | 502.68 Thousand |
| Other non-cash items | - | 2.86 Million | 2.64 Million | 6.27 Million | 4.58 Million | 1.7 Million |
| Investing Cash Flow | -140.12 Thousand | 318.06 Thousand | -629.96 Thousand | -811.79 Thousand | -540.43 Thousand | -522.18 Thousand |
| Investments in PPE | -140.12 Thousand | -99.62 Thousand | -1.52 Million | -1.8 Million | -536.09 Thousand | -207.89 Thousand |
| Acquisitions | - | - | 85.84 Thousand | -202.84 Thousand | -4339.07 | -314.28 Thousand |
| Investment purchases | - | - | -88.42 Thousand | - | - | - |
| Sales/Maturities of investments | - | - | - | 164.56 Thousand | - | - |
| Other Investing Activities | - | 417.69 Thousand | 899.42 Thousand | 1.03 Million | - | - |
| Financing Cash Flow | 14.86 Million | 5.1 Million | 5.52 Million | 9.26 Million | 5.82 Million | 14.89 Thousand |
| Debt repayment | - | -3.75 Million | -34.82 Thousand | -3.12 Million | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -596.77 Thousand | -317.83 Thousand | -764.06 Thousand | -1.2 Million | - | - |
| Common Stock Issuance | 15.7 Million | 1.45 Million | 5.63 Million | 6.28 Million | 5.93 Million | 14.89 Thousand |
| Other Financing Activities | -238.67 Thousand | -200.95 Thousand | -263 Thousand | -255.99 Thousand | -971.28 Thousand | - |
| Accounts receivables | - | 737.62 Thousand | 733.1 Thousand | -1.2 Million | 151.51 Thousand | -162.64 Thousand |
| Accounts payables | - | 98.97 Thousand | 925.98 Thousand | -445.61 Thousand | 288.86 Thousand | 349.09 Thousand |
| Inventory | - | 249.38 Thousand | -547.29 Thousand | -255.53 Thousand | -146.79 Thousand | 316.22 Thousand |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | 239.82 Thousand | 1.06 Million | 2.95 Million | 1.04 Million | 1.29 Million | 5.51 Million |
| Cash at end of period | 702.87 Thousand | 125.83 Thousand | 1.06 Million | 2.95 Million | 1.04 Million | 1.29 Million |
| Capital Expenditure | -140.12 Thousand | -99.62 Thousand | -1.52 Million | -1.8 Million | -536.09 Thousand | -207.89 Thousand |
| Effect of forex changes on cash | -658.00 | 9463.00 | -15.29 Thousand | -7799.00 | -15.86 Thousand | - |
| Net cash flow / Change in cash | 463.04 Thousand | -943.6 Thousand | -1.88 Million | 1.9 Million | -254.13 Thousand | -4.21 Million |
| Free Cash Flow | -140.12 Thousand | -6.38 Million | -8.41 Million | -8.32 Million | -6.08 Million | -3.71 Million |
| Breakdown | 2023 Q4 | 2023 Q2 | 2022 FY | 2022 Q4 | 2022 Q2 | 2021 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -3.78 Million | -5.21 Million | -10.92 Million | -6.13 Million | -7.31 Million | -11.53 Million |
| Depreciation & Amortization | 350.14 Thousand | 198.83 Thousand | 394.54 Thousand | 90.45 Thousand | 93.37 Thousand | 229.73 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | 1.08 Million | - | - | 1.11 Million |
| Other non-cash items | -93.35 Thousand | 2.67 Million | 2.86 Million | 2.41 Million | 3.57 Million | 2.64 Million |
| Investing Cash Flow | -9012.18 | 37.96 Thousand | 318.06 Thousand | 300.77 Thousand | 391.86 Thousand | -629.96 Thousand |
| Investments in PPE | -9012.18 | 24.17 Thousand | -99.62 Thousand | -132.93 Thousand | -182.18 Thousand | -1.52 Million |
| Acquisitions | - | - | - | - | - | 85.84 Thousand |
| Investment purchases | - | - | - | - | - | -88.42 Thousand |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | 13.78 Thousand | 417.69 Thousand | 433.7 Thousand | 574.04 Thousand | 899.42 Thousand |
| Financing Cash Flow | 7.57 Million | 2.24 Million | 5.1 Million | 3.07 Million | -42.41 Thousand | 5.52 Million |
| Debt repayment | - | -833.86 Thousand | -3.75 Million | -3.14 Million | -34.82 Thousand | -34.82 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -317.83 Thousand | - | - | -764.06 Thousand |
| Common Stock Issuance | 7.63 Million | 1.45 Million | 1.45 Million | - | -7270.98 | 5.63 Million |
| Other Financing Activities | - | - | -200.95 Thousand | - | - | -263 Thousand |
| Accounts receivables | - | - | 737.62 Thousand | - | - | 733.1 Thousand |
| Accounts payables | - | - | 98.97 Thousand | - | - | 925.98 Thousand |
| Inventory | - | - | 249.38 Thousand | - | - | -547.29 Thousand |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | 125.83 Thousand | 638.73 Thousand | 1.06 Million | 1.06 Million | 4.32 Million | 2.95 Million |
| Cash at end of period | 3.46 Million | 125.83 Thousand | 125.83 Thousand | 638.73 Thousand | 1.06 Million | 1.06 Million |
| Capital Expenditure | -9012.18 | 24.17 Thousand | -99.62 Thousand | -132.93 Thousand | -182.18 Thousand | -1.52 Million |
| Effect of forex changes on cash | - | - | 9463.00 | - | - | -15.29 Thousand |
| Net cash flow / Change in cash | 3.34 Million | -512.89 Thousand | -943.6 Thousand | -430.7 Thousand | -3.25 Million | -1.88 Million |
| Free Cash Flow | -4.23 Million | -2.72 Million | -6.38 Million | -3.93 Million | -4.01 Million | -8.41 Million |
7040
CNE
CAC
MNAT
RADHIKAJWE
SIAM